右归丸对绝经后骨量减少肾阳虚型的临床研究
Clinical study of Yougui Pill on postmenopausal osteopenia with kidney yang deficiency
  
DOI:10.3969/j.issn.1006-7108.2022.08.013
中文关键词:  右归丸  绝经后骨质疏松症  温针灸  骨量减少  肾阳虚
英文关键词:Yougui pill  postmenopausal osteoporosis  warm acupuncture  osteopenia  kidney yang deficiency
基金项目:基金项目:陕西省科技厅重点研发项目(2021SF419);咸阳市科技局社会发展科技重点研发计划(2020k02-109);刘德玉名老中医药专家传承工作室项目、陕西中医药大学学科建设创新团队(骨关节及脊椎退行性疾病中西医结合防治创新团队2019YL-02)
作者单位
梁壮1 董博2* 袁普卫2 杨锋2 刘德玉2 李珣2 康武林2 王占奎2 杨蕾1 1. 陕西中医药大学 2. 陕西中医药大学附属医院骨科 
摘要点击次数: 575
全文下载次数: 0
中文摘要:
      摘要:目的 观察右归丸对绝经后骨量减少肾阳虚型的临床研究。方法 选取2020年10月-2021年6月在陕西中医药大学附属医院康复医学科接受治疗的绝经后骨量减少肾阳虚型患者81人,通过随机数字法分为治疗组(n=40)和对照组(n=41),对照组口服碳酸钙维D3片及行温针灸,治疗组在对照组基础上加服右归丸,总疗程为12周。对比治疗组及对照组治疗后总有效率、治疗前和治疗后骨代谢标志物[(血清骨钙素(BGP)、25-羟维生素D3、β胶原降解产物(β-CTX)、Ⅰ型前胶原氨基端前肽(PINP)]、性激素[促黄体生成素(LH)、血清雌二醇(E2)、促卵泡激素(FSH)]水平变化、生活质量量表躯体健康总评分(PCS)、左髋关节和L1~4的骨密度(BMD)、中医证候评分和不良反应率。结果 治疗后对照组与治疗组总有效率分别为71.05 %、86.84 %(P<0.05);治疗后两组患者骨代谢标志物水平、中医证候评分均显著低于治疗前,且治疗组较对照组显著降低(P<0.05);治疗后两组患者BMD、LH、E2、FSH水平、PCS评分均较治疗前显著提高,且治疗组显著高于对照组(P<0.05);治疗组不良反应发生率为(3/38)7.89 %,对照组为(2/38)5.26 %(P>0.05)。结论 右归丸治疗绝经后骨量减少肾阳虚型患者疗效较好,能够降低中医证候评分,增加骨密度,调节骨代谢,提高PCS评分,改善生活质量,且不良反应较少,值得临床推广。
英文摘要:
      Abstract:Objective To observe the clinical study of Yougui pill onPostmenopausal osteopenia with kidney yang deficiency. Methods A total of 81 postmenopausal patients with osteopenia and kidney-yang deficiency who were treated in shaanxi university of traditional Chinese medicine hospital rehabilitation medicine from October 2020 to June 2021 were selected, who were divided into the treatment group (n=40) and the control group (n=41) through the random number method.The control group was given calcium carbonate and vitamin D3 tablets orally and warm acupuncture, while the treatment group was given Yougui Pill on the basis of the control group. The total course of treatment was 12 weeks. The total response rate of the treatment group and the control group after treatment, Changes of bone metabolic markers [serum osteocalcin (BGP), 25-hydroxyvitamin D3, β -collagen degradation product (β-CTX), type Ⅰ procollagen amino-terminal propeptide (PINP)], sex hormones [luteinizing hormone (LH), serum estradiol (E2), follicle-stimulating hormone (FSH)], bone density of left hip joint and L1-4 before and after treatment Degree (BMD), TCM syndrome score, total physical health score of Quality of Life Scale (PCS) and adverse reaction rate. Results After treatment, the total effective rate of control group and treatment group was 71.05 % and 86.84 %, respectively (P<0.05). After treatment, the levels of bone metabolism markers and TCM syndrome scores in 2 groups were significantly lower than before, and the levels in treatment group were significantly lower than that in control group (P<0.05). After treatment, the levels of BMD, LH, E2, FSH and PCS score in 2 groups were significantly increased compared with before treatment, and the treatment group was significantly higher than the control group (P<0.05). The incidence of adverse reactions in the treatment group was 7.89 % (3/38) and 5.26 % (2/38) in the control group (P>0.05). Conclusion Yougui pill has a good curative effect in the treatment of postmenopausal patients with reduced bone mass due to kidney Yang deficiency, which reduces TCM syndrome score, increases bone mineral density, regulates bone metabolism, improves PCS score, and improves quality of life. With fewer adverse reactions, yougui Pill is worthy of clinical promotion.
查看全文  查看/发表评论  下载PDF阅读器
关闭
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=3C06DB566315F8DC59AE367DE863DD0B7029DDB8B0C2BB260C961638B0BF416987B44C32711F77B78272EF65ABB429642F466C0271126B2B04571005FDA6B76B85BD7ABEE6C423663D26EFA68F3D5C6F477D15F21528BEBD&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=527A01A248DACB72&jid=CA678592D11E309E8E3FB3B2BFE9BE1A&yid=885CEFEC57DA488F&aid=68F7EBB7E610720F435BB8E0566E260B&vid=&iid=5D311CA918CA9A03&sid=4E85BC78FC25985C&eid=C4690645D4CCDCE7&fileno=202208013&flag=1&is_more=0"> var my_pcid="A9DB1C13C87CE289EA38239A9433C9DC"; var my_cid="527A01A248DACB72"; var my_jid="CA678592D11E309E8E3FB3B2BFE9BE1A"; var my_yid="885CEFEC57DA488F"; var my_aid="68F7EBB7E610720F435BB8E0566E260B";